943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SCW. Sandborn, P. J. Rutgeerts, Jewel Johanns et al.|Gastroenterology|2012Cited by 27
P142 Subcutaneously administered golimumab induction therapy improves health states measured by EQ-5D in patients with moderately to severely active ulcerative colitis: results from PURSUIT-SCPeter G. Gibson, W. Sandborn, B. Feagan et al.|Journal of Crohn s and Colitis|2013Cited by 2